TitleAssistant Professor
InstitutionMD Anderson
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Liu S, Johnson VE. A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics. 2016 Apr; 17(2):249-63. PMID: 26486139; PMCID: PMC5006115.
      Citations: 13     Fields:    Translation:Humans
    2. Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Stat Med. 2015 May 10; 34(10):1681-94. PMID: 25626429.
      Citations: 8     Fields:    Translation:Humans
    3. Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics. 2014 Jun; 70(2):366-77. PMID: 24575781; PMCID: PMC4061263.
      Citations: 1     Fields:    Translation:Humans
    4. Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics. 2013 Dec; 69(4):914-24. PMID: 24328715; PMCID: PMC3970927.
      Citations: 1     Fields:    Translation:Humans
    5. Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM, Blumenschein GR. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75. PMID: 24166906; PMCID: PMC3905243.
      Citations: 28     Fields:    Translation:Humans
    6. Liu S, Cai C, Ning J. Up-and-down designs for phase I clinical trials. Contemp Clin Trials. 2013 Sep; 36(1):218-27. PMID: 23856381; PMCID: PMC4217164.
      Citations: 10     Fields:    Translation:Humans
    7. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61. PMID: 23584298; PMCID: PMC5118909.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    8. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52. PMID: 23059780; PMCID: PMC5161038.
      Citations: 8     Fields:    Translation:Humans
    9. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39. PMID: 22247021; PMCID: PMC3274509.
      Citations: 199     Fields:    Translation:HumansCells
    10. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11. PMID: 21892101.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    11. Momoh AO, Yu P, Skoracki RJ, Liu S, Feng L, Hanasono MM. A prospective cohort study of fibula free flap donor-site morbidity in 157 consecutive patients. Plast Reconstr Surg. 2011 Sep; 128(3):714-720. PMID: 21572380.
      Citations: 23     Fields:    Translation:Humans
    12. Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9. PMID: 21881030; PMCID: PMC4028708.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    13. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53. PMID: 22586319; PMCID: PMC4211116.
      Citations: 329     Fields:    Translation:HumansCTClinical Trials
    14. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med. 2011 May 20; 30(11):1218-29. PMID: 21432894; PMCID: PMC3086983.
      Citations: 7     Fields:    Translation:Humans
    15. Savar A, Esmaeli B, Ho H, Liu S, Prieto VG. Conjunctival melanoma: local-regional control rates, and impact of high-risk histopathologic features. J Cutan Pathol. 2011 Jan; 38(1):18-24. PMID: 20860727.
      Citations: 12     Fields:    Translation:Humans
    16. Lee JJ. Bayesian adaptive randomization designs for targeted agent development. Clin Trials. 2010 Oct; 7(5):584-96. PMID: 20571130; PMCID: PMC5110207.
      Citations: 38     Fields:    Translation:Humans
    17. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer. 2010 Feb; 10(1):46-51. PMID: 20133258.
      Citations: 5     Fields:    Translation:Humans
    18. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res. 2009 Sep 01; 15(17):5359-68. PMID: 19706809; PMCID: PMC2893045.
      Citations: 77     Fields:    Translation:HumansCells
    19. Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009 Aug; 16(8):2181-7. PMID: 19475451; PMCID: PMC2711905.
      Citations: 21     Fields:    Translation:Humans
    20. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer. 2009 Mar 01; 115(5):1091-9. PMID: 19165805.
      Citations: 35     Fields:    Translation:Humans
    21. William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol. 2009 Feb; 32(1):15-9. PMID: 19194117; PMCID: PMC5120668.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    22. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials. 2008; 5(3):181-93. PMID: 18559407; PMCID: PMC5481999.
      Citations: 63     Fields:    Translation:Humans
    23. Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR, Lee JH, Couriel D. Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol. 2008 Apr; 103(4):982-9. PMID: 18028511.
      Citations: 28     Fields:    Translation:Humans
    24. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72. PMID: 17620427.
      Citations: 45     Fields:    Translation:HumansCells
    25. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Statistics in Medicine. 33:4017-4028.
    26. Erratum. Cancer. 115:1588.
    27. Bayesian optimal interval designs for phase I clinical trials. Journal of the Royal Statistical Society. Series C: Applied Statistics. 64:507-523.
    28. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers. Journal of the Royal Statistical Society. Series C: Applied Statistics. 64:635-650.
    29. Journal of the American Statistical Association. 109:525-536.
    30. Bayesian Two-Stage Biomarker-Based Adaptive Design for Targeted Therapy Development. Statistics in Biosciences.
    31. Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity. Annals of Applied Statistics. 7:2138-2156.
    32. Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics. 17:549-560.
    33. A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics. 17:249-263.
    34. A bayesian dose-finding design for drug combination trials with delayed toxicities. Bayesian Analysis. 8:703-722.
    LIU's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (195)
    Co-Authors (41)
    Similar People (60)
    Same Department Expand Description